SCHEMBL731589

SCHEMBL731589

[c]1ccc2c(c1)nc(C1CC1)n2-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.43
PDE10A Q9Y233 1/20 0.43
SCN9A Q15858 3/20 0.41
DRD1 P21728 3/20 0.39
DRD5 P21918 3/20 0.39
KCNH2 Q12809 1/20 0.37
HTT P42858 2/20 0.36
MAPK1 P28482 2/20 0.36
HSD17B10 Q99714 2/20 0.36
ALDH1A1 P00352 2/20 0.36
ALOX15 P16050 1/20 0.36
KDM4E B2RXH2 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CHRM2 P08172 2/20 0.35
CHRM4 P08173 2/20 0.35
CHRM5 P08912 2/20 0.35
CHRM1 P11229 2/20 0.35
CHRM3 P20309 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10818327 0.82 SCN9A (0.55) CYP1A2PDE10ASCN9ADRD1DRD5
SCHEMBL694397 0.76 MAPK1 (0.65) CYP1A2PDE10AHTTMAPK1HSD17B10
SCHEMBL3613081 0.76 HTR2B (0.39) PDE10A
SCHEMBL8022188 0.75 USP2 (0.54) CYP1A2PDE10ASCN9ADRD1DRD5
SCHEMBL732846 0.75 ESR1 (0.54) HTTMAPK1ALDH1A1GAA
SCHEMBL7887660 0.72 SCN9A (0.50) CYP1A2PDE10ASCN9AHTTMAPK1
SCHEMBL6439085 0.71 ESR2 (0.56) CYP1A2PDE10ASCN9AKCNH2HTT
SCHEMBL19127878 0.69 HTR2B (0.41) PDE10AKCNH2CHRM1
SCHEMBL19127648 0.68 TAAR1 (0.40) PDE10A
SCHEMBL732942 0.67 HPGD (0.58) HSD17B10ALDH1A1KDM4ESMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 CYP1A2 98/4885PDE10A 4427/4885SCN9A 3567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.